Search Results - "Lerma, V."

Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association by Rangaswami, Janani, Bhalla, Vivek, Blair, John E.A, Chang, Tara I, Costa, Salvatore, Lentine, Krista L, Lerma, Edgar V, Mezue, Kenechukwu, Molitch, Mark, Mullens, Wilfried, Ronco, Claudio, Tang, W.H Wilson, McCullough, Peter A

“…Cardiorenal syndrome encompasses a spectrum of disorders involving both the heart and kidneys in which acute or chronic dysfunction in 1 organ may induce acute…”
Get full text

Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies by Rangaswami, Janani, Mathew, Roy O, Parasuraman, Raviprasenna, Tantisattamo, Ekamol, Lubetzky, Michelle, Rao, Swati, Yaqub, Muhammad S, Birdwell, Kelly A, Bennett, William, Dalal, Pranav, Kapoor, Rajan, Lerma, Edgar V, Lerman, Mark, McCormick, Nicole, Bangalore, Sripal, McCullough, Peter A, Dadhania, Darshana M

“…Kidney transplantation (KT) is the optimal therapy for end-stage kidney disease (ESKD), resulting in significant improvement in survival as well as quality of…”
Get full text

Class effects of SGLT2 inhibitors on cardiorenal outcomes by Kluger, Aaron Y, Tecson, Kristen M, Lee, Andy Y, Lerma, Edgar V, Rangaswami, Janani, Lepor, Norman E, Cobble, Michael E, McCullough, Peter A

“…To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58),…”
Get full text

The Evolution of the Journal Club: From Osler to Twitter by Topf, Joel M., MD, Sparks, Matthew A., MD, Phelan, Paul J., MD, Shah, Nikhil, MBBS, DNB, Lerma, Edgar V., MD, Graham-Brown, Matthew P.M., MD, MRes, Madariaga, Hector, MD, Iannuzzella, Francesco, MD, Rheault, Michelle N., MD, Oates, Thomas, MD, PhD, Jhaveri, Kenar D., MD, Hiremath, Swapnil, MD, MPH

“…Journal clubs have typically been held within the walls of academic institutions and in medicine have served the dual purpose of fostering critical appraisal…”
Get full text

Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD by Carr, Edward J., Kronbichler, Andreas, Graham-Brown, Matthew, Abra, Graham, Argyropoulos, Christos, Harper, Lorraine, Lerma, Edgar V., Suri, Rita S., Topf, Joel, Willicombe, Michelle, Hiremath, Swapnil

“…The effects of the coronavirus disease-2019 (COVID-19) pandemic, particularly among those with chronic kidney disease (CKD), who commonly have defects in…”
Get full text

Diabetic ketoacidosis by Calimag, Angela Pauline P., Chlebek, Sylvia, Lerma, Edgar V., Chaiban, Joumana T.

“…Diabetic ketoacidosis (DKA) is a form of a hyperglycemic emergency mainly characterized by the triad of hyperglycemia, ketosis, and anion gap metabolic…”
Get full text

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator? by Krishnan, Anoushka, Shankar, Mythri, Lerma, Edgar V., Wiegley, Nasim

“…Sodium/glucose cotransporter 2 (SGLT2) inhibitors have rapidly emerged as a novel therapy to reduce the rate of progression of chronic kidney disease (CKD)…”
Get full text

A Review of Focal Segmental Glomerulosclerosis Classification With a Focus on Genetic Associations by Bonilla, Marco, Efe, Orhan, Selvaskandan, Haresh, Lerma, Edgar V., Wiegley, Nasim

“…Focal segmental glomerulosclerosis (FSGS) defines a distinct histologic pattern observed in kidney tissue that is linked to several distinct underlying causes,…”
Get full text

Prevalence of Atrial Fibrillation and Its Predictors in Nondialysis Patients with Chronic Kidney Disease by Ananthapanyasut, Wanwarat, Napan, Sirikarn, Rudolph, Earl H, Harindhanavudhi, Tasma, Ayash, Husam, Guglielmi, Kelly E, Lerma, Edgar V

“…Chronic kidney disease (CKD) increases systemic inflammation, which is implicated in development and maintenance of atrial fibrillation (AF); therefore, we…”
Get full text

Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy by Colbert, Gates B, Madariaga, Hector M, Gaddy, Anna, Elrggal, Mohamed E, Lerma, Edgar V

“…Chronic kidney disease guidelines and disease modifying therapy have seen a dramatic shift in the last 5 years. The SGLT2 inhibitor class of medications has…”
Get full text

Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia by Colbert, Gates, Sannapaneni, Shilpa, Lerma, Edgar V

“…Hyperkalemia remains one of the most difficult consequences of disease state and treatment for patients with chronic kidney disease, heart failure, and…”
Get full text

Improving Care Coordination Between Nephrology and Primary Care: A Quality Improvement Initiative Using the Renal Physicians Association Toolkit by Haley, William E., MD, Beckrich, Amy L., BA, Sayre, Judith, PhD, McNeil, Rebecca, PhD, Fumo, Peter, MD, Rao, Vijaykumar M., MD, Lerma, Edgar V., MD

“…Background Individuals at risk for chronic kidney disease (CKD), including those with diabetes mellitus and hypertension, are prevalent in primary care…”
Get full text

Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis by Rivera, Frederick Berro, Tang, Vincent Anthony S., De Luna, Deogracias Villa, Lerma, Edgar V., Vijayaraghavan, Krishnaswami, Kazory, Amir, Shah, Nilay S., Volgman, Annabelle Santos

“…In patients with heart failure (HF), randomized controlled trials (RCTs) of sodium-glucose transporter-2 inhibitors (SGLT-2is) have proven to be effective in…”
Get full text

Positive and negative impact of social media in the COVID-19 era by Venegas-Vera, A Verner, Colbert, Gates B, Lerma, Edgar V

“…Social Media usage has been shown to increase in situations of natural disaster and other crises. It is crucial for the scientific community to understand how…”
Get full text

Utility of telemedicine in the COVID-19 era by Colbert, Gates B, Venegas-Vera, A Verner, Lerma, Edgar V

“…Previously it has been demonstrated that telehealth (TH) could help cover the gaps in health attention in remote locations. Today the expanded capabilities…”
Get full text

Vemurafenib‐induced toxic epidermal necrolysis: possible cross‐reactivity with other sulfonamide compounds by Bellón, T., Lerma, V., González‐Valle, O., González Herrada, C., Abajo, F.J.

“…Summary Vemurafenib is a newly licensed target‐directed medication. It has been proven to improve the survival of patients with metastatic melanoma and the…”
Get full text

Care in patients with epidermal necrolysis in burn units. A nursing perspective by Lerma, V., Macías, M., Toro, R., Moscoso, A., Alonso, Y., Hernández, O., de Abajo, F.J.

“…•Epidermal necrolysis care varies in burn units.•Few burn units in Spain have nursing care protocols on epidermal necrolysis.•Some interventions are outdated…”
Get full text

Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study by de Abajo, Francisco J, Rodríguez-Miguel, Antonio, Rodríguez-Martín, Sara, Lerma, Victoria, García-Lledó, Alberto

“…In the first wave of the COVID-19 pandemic, the hypothesis that angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs)…”
Get full text

Cardiovascular disease and chronic kidney disease by Gargiulo, Richard, DO, Suhail, Faten, MD, Lerma, Edgar V., MD

Get full text

Hypertension and chronic kidney disease by Gargiulo, Richard, DO, Suhail, Faten, MD, Lerma, Edgar V., MD

Get full text